Drug-industry lobbying that weakened DEA distributor enforcement

The opioid crisis was getting worse, deaths were rising, and at the same time, something was happening in Washington that attracted far less attention.

According to an investigation by The Washington Post and 60 Minutes, pharmaceutical lobbyists had been pushing for changes that ultimately weakened the DEA’s ability to go after prescription drug distributors.

The effort reportedly involved targeted lobbying and congressional action, at a time when prescription opioids were already becoming a growing public-health crisis.

That combination is what made the story so unsettling , an industry with billions at stake, a federal agency responsible for controlling the distribution of powerful drugs, and lawmakers changing the rules while the consequences were becoming harder to ignore.

The investigation reported the connection between the lobbying campaign and the weakening of DEA enforcement powers , but the claims about intent and causation should be understood as investigative reporting rather than an established judicial finding.

Source, The Washington Post and 60 Minutes investigation.